| Literature DB >> 35923861 |
Kamil Rodak1, Izabela Kokot1, Aleksandra Kryla1, Ewa Maria Kratz1.
Abstract
We verified whether caffeinated coffee consumption influenced the concentrations of prolactin (PRL) and oxidative stress parameters: total antioxidant status (TAS), ferric reducing antioxidant power (FRAP), total oxidant status (TOS), oxidative stress index (OSI), advanced oxidation protein products (AOPP), uric acid (UA), total bilirubin (T-Bil), albumin (ALB), iron (Fe), calcium (Ca), magnesium (Mg), and inflammatory marker C-reactive protein (CRP)-in blood sera obtained at 15, 60, and 120 minutes after caffeinated coffee intake, in relation to the fasting point. The study participants were 33 young, healthy, nonsmoking volunteers (15 men, 18 women) aged 19-29 years. PRL concentrations significantly decreased (p < 0.05) after consumption, except at time point 15' in men (p > 0.05). In women, FRAP levels significantly increased over time, and significant changes were also observed for UA at 120' and ALB at 15'. In men, significant changes were found for levels of AOPP at 15', T-Bil and ALB at 15', iron at 60' and 120', and calcium at 120'. There were no significant differences in the levels of other examined parameters between the defined time points. In conclusion, the substances contained in caffeinated coffee decrease the level of prolactin and may also have an impact on selected parameters of oxidative stress, which could be the basis of future research focused on the identification of new therapeutic targets.Entities:
Mesh:
Substances:
Year: 2022 PMID: 35923861 PMCID: PMC9343215 DOI: 10.1155/2022/1735204
Source DB: PubMed Journal: Oxid Med Cell Longev ISSN: 1942-0994 Impact factor: 7.310
Figure 1The main ingredients of coffee with an antioxidant effect.
General characteristics of the study groups.
| Parameters | Gender | |
|---|---|---|
| Women | Men | |
| Mean ± SD | Mean ± SD | |
| Age (years) | 22.17 ± 1.86 | 23.80 ± 2.60 |
| Height (m) | 1.68 ± 0.07 | 1.82 ± 0.05 |
| Body mass (kg) | 64.87 ± 15.38 | 75.02 ± 11.11 |
| BMI (kg/m2) | 22.85 ± 4.54 | 22.52 ± 2.62 |
| WHR | 0.77 ± 0.06 | 0.84 ± 0.11 |
| WBC (G/L) | 6.75 ± 1.86 | 5.63 ± 1.08 |
| Caffeine consumption (% of people who consume caffeine) | 100% | 100% |
| The mean frequency of consumption of caffeinated beverages (times/day) | 2.06 ± 1.47 | 2.27 ± 1.03 |
| The frequency of consumption of caffeinated coffee (cups/day) | 1.50 ± 0.86 | 1.93 ± 0.96 |
| The type of consumed coffee (number of volunteers) | ||
| Instant | 3 | 3 |
| Brewed coffee | 7 | 6 |
| Espresso coffee | 7 | 6 |
| Other | 1 | 0 |
BMI: body mass index (body mass (kg)/height (m2)); WHR: waist-hip ratio (waist circumference/hip circumference); WBC: white blood cell count; SD: standard deviation; N: number of participants.
Figure 2Schematic representation of experimental procedures. PRL: prolactin; OS: oxidative stress.
Figure 3The concentration values of prolactin for women and men. SD: standard deviation; p value was calculated versus time point 0', and a two-tailed p value of less than 0.05 was considered significant. 0', 15', 60', and 120': time points of measurements.
The concentrations of oxidative-antioxidant balance parameters, elements, and inflammatory marker.
| Women | Men | |||||||
|---|---|---|---|---|---|---|---|---|
| 0' | 15' | 60' | 120' | 0' | 15' | 60' | 120' | |
| Mean ± SD | Mean ± SD | Mean ± SD | Mean ± SD | Mean ± SD | Mean ± SD | Mean ± SD | Mean ± SD | |
| TAC | ||||||||
| TAS (mmol/L) | 1.58 ± 0.08 | 1.55 ± 0.07 | 1.59 ± 0.08 | 1.58 ± 0.08 | 1.65 ± 0.08 | 1.68 ± 0.13 | 1.66 ± 0.08 | 1.66 ± 0.08 |
| FRAP (mmol/L) | 1.11 ± 0.11 | 1.14 ± 0.11 | 1.14 ± 0.10 | 1.13 ± 0.10 | 1.31 ± 0.19 | 1.33 ± 0.16 | 1.31 ± 0.17 | 1.33 ± 0.16 |
| TOS and OSI | ||||||||
| TOS ( | 1.72 ± 0.99 | 1.74 ± 0.96 | 2.04 ± 1.76 | 1.99 ± 2.27 | 1.94 ± 1.17 | 1.86 ± 1.01 | 1.55 ± 0.60 | 1.45 ± 0.68 |
| OSI (arbitrary units) | 1.10 ± 0.66 | 1.12 ± 0.62 | 1.27 ± 1.03 | 1.24 ± 1.32 | 1.17 ± 0.70 | 1.13 ± 0.64 | 0.93 ± 0.35 | 0.88 ± 0.43 |
| AOPP | ||||||||
| AOPP ( | 95.46 ± 30.15 | 87.49 ± 14.16 | 87.08 ± 16.76 | 87.56 ± 23.74 | 106.83 ± 39.79 | 97.00 ± 32.38 | 101.98 ± 35.05 | 98.72 ± 36.40 |
| Low-molecular-weight antioxidants | ||||||||
| UA (mg/dL) | 4.58 ± 0.71 | 4.54 ± 0.70 | 4.50 ± 0.67 | 4.48 ± 0.59 | 5.70 ± 1.16 | 5.74 ± 0.96 | 5.74 ± 1.01 | 5.76 ± 0.93 |
| T-Bil (mg/dL) | 0.52 ± 0.21 | 0.53 ± 0.22 | 0.56 ± 0.27 | 0.55 ± 0.27 | 0.78 ± 0.51 | 0.82 ± 0.53 | 0.87 ± 0.53 | 0.89 ± 0.56 |
| ALB (g/dL) | 4.59 ± 0.46 | 4.42 ± 0.30 | 4.65 ± 0.50 | 4.67 ± 0.53 | 4.72 ± 0.38 | 4.50 ± 0.18 | 4.55 ± 0.28 | 4.78 ± 0.44 |
| Elements | ||||||||
| Fe ( | 96.39 ± 41.15 | 95.06 ± 41.33 | 100.78 ± 45.73 | 101.44 ± 47.71 | 114.47 ± 43.59 | 114.80 ± 43.59 | 118.27 ± 46.04 | 121.40 ± 45.13 |
| Ca (mg/dL) | 9.48 ± 0.47 | 9.51 ± 0.39 | 9.63 ± 0.40 | 9.63 ± 0.41 | 9.49 ± 0.36 | 9.49 ± 0.40 | 9.59 ± 0.44 | 9.66 ± 0.37 |
| Mg (mg/dL) | 2.29 ± 0.14 | 2.25 ± 0.15 | 2.30 ± 0.11 | 2.34 ± 0.15 | 2.33 ± 0.15 | 2.31 ± 0.16 | 2.27 ± 0.18 | 2.33 ± 0.20 |
| Inflammatory marker | ||||||||
| CRP (mg/L) | 2.06 ± 2.34 | 2.01 ± 2.28 | 2.07 ± 2.42 | 2.09 ± 2.45 | 0.58 ± 0.62 | 0.58 ± 0.60 | 0.58 ± 0.62 | 0.59 ± 0.62 |
The Wilcoxon test was used to check the differences between time point 0' and other analyzed time points. A two-tailed p value of less than 0.05 was considered significant. p: significant differences versus time point 0'. ALB: albumin; AOPP: advanced protein oxidation products; Ca: calcium; CRP: C-reactive protein; SD: standard deviation; Fe: iron; FRAP: ferric reducing antioxidant power; Mg: magnesium; OSI: oxidative stress index (TOS/TAS); TAC: total antioxidant capacity; TAS: total antioxidant status; TOS: total oxidant status; T-Bil: bilirubin; UA: uric acid.
The significant correlations between concentrations of determined parameters.
| Parameters compared | 0' | 15' | 60' | 120' | ||||
|---|---|---|---|---|---|---|---|---|
|
|
|
|
|
|
|
|
| |
| Women | ||||||||
| Ca vs. ALB | 0.586 | 0.010 | 0.667 | 0.002 | 0.612 | 0.007 | 0.646 | 0.004 |
| Ca vs. CRP | -0.559 | 0.016 | -0.541 | 0.020 | -0.552 | 0.017 | -0.516 | 0.028 |
| CRP vs. ALB | -0.717 | <0.001 | -0.735 | <0.001 | -0.717 | 0.001 | -0.664 | 0.003 |
| FRAP vs. UA | 0.830 | <0.001 | 0.904 | <0.001 | 0.884 | <0.001 | 0.687 | 0.002 |
| Men | ||||||||
| Ca vs. ALB | 0.503 | 0.056 | 0.560 | 0.030 | 0.704 | 0.003 | 0.558 | 0.031 |
| Ca vs. Mg | 0.636 | 0.011 | 0.548 | 0.034 | 0.710 | 0.003 | 0.757 | 0.001 |
| FRAP vs. UA | 0.961 | <0.001 | 0.946 | <0.001 | 0.968 | <0.001 | 0.957 | <0.001 |
| TAS vs. UA | 0.893 | <0.001 | 0.821 | <0.001 | 0.862 | <0.001 | 0.811 | <0.001 |
| FRAP vs. TAS | 0.859 | <0.001 | 0.728 | 0.002 | 0.803 | <0.001 | 0.706 | 0.003 |
A two-tailed p value of less than 0.05 was considered significant. ALB: albumin; Ca: calcium; CRP: C-reactive protein; FRAP: ferric reducing antioxidant power; Mg: magnesium; R: correlation coefficient; TAS: total antioxidant status; UA: uric acid.
Figure 4Scheme of interactions between oxidative stress development and levels of serum oxidative stress parameters in relation to time points of measurement after caffeinated coffee consumption. ALB: albumin; Ca: calcium; FRAP: ferric reducing antioxidant power; PRL: prolactin; T-Bil: total bilirubin; UA: uric acid. Versus time point 0': NS: not significant; ↑: significantly increased; ↓: significantly decreased.